The US Food and Drug Administration gave green light to a new drug to treat Alzheimer’s.
Leqembi has shown to slow patients' rate of cognitive decline.
The FDA’s approval will likely trigger broader coverage of the drug, bringing it within reach of patients.
Veuer’s Maria Mercedes Galuppo has the story.